Articles
Isabel Mestres: The Doer
Global health has become very good at diagnosing problems but far less effective at implementing solutions. That gap is where Isabel Mestres has built her career. As CEO of City Cancer Challenge, she is known not as a theorist or…
OncoCorridor
As a medical student, we had a lecture on how to deliver bad news.Then, as an oncology fellow, we had it again.And as frontline clinicians, we practice it every day. “Your child has leukemia…You have cancer…Your child has Ewing sarcoma…You…
Lived Experience of People Affected by Cancer
Too Much Hope is a False Hope K. still remembers the moment she heard the diagnosis. The room felt suddenly smaller, the air heavier, and time strangely suspended. “You wake up in a void, alone and scared,” she says. “But…
Translating Global Excellence into Local Impact: Dr Fatjona Kraja and the Challenge of Transforming Radiation Oncology in Albania
Radiation oncology is one of the most technologically sophisticated and intellectually demanding disciplines in modern medicine. Yet, for Dr Fatjona Kraja, newly appointed Faculty member of the European School of Oncology (ESO) College, the field is defined not only by…
“Hope is Constant “: From Isolation and Fear to Connection, Purpose, and Global Impact
Hope as a Guiding Mantra One of my friends, a retired oncology nurse in Scotland, where I live, has become a source of hope for my family and me, and her words have become a mantra: hope is constant. Prior…
Michael Gnant at the Crossroads of Oncology: Precision, Restraint, and the Courage to Challenge Orthodoxy
Sixteen years ago, Dr. Michael Gnant was portrayed in CancerWorld as a surgical oncologist unafraid to push boundaries in breast cancer care. Today, his perspective reflects not retreat but evolution. The boundary-pusher remains, but his focus has widened. His work…
From Dalian to Houston and Back to Yemen: Bridging the Global Oncology Divide
A Global Summit, a Personal Reckoning At the European Society for Medical Oncology (ESMO) Leadership Summit in Singapore, discussions moved rapidly from antibody–drug conjugates to next-generation sequencing and the expanding role of immunotherapy. Clinical trial curves filled large screens, and…
The Day Immunotherapy Went Off-Patent
In oncology, some milestones arrive with applause. Others arrive quietly. This year, one of the most important cancer drugs of the modern era begins to lose its monopoly. Nivolumab, one of the first PD-1 inhibitors to reach patients, is set…
Leading with Listening: Why Isabel Rubio Believes Europe’s Cancer Future Depends on Trust, Equity, and Political Courage
Leadership in oncology is often measured in breakthroughs, budgets, and policy frameworks. But for Dr. Isabel Rubio, President of the European Cancer Organisation (ECO), leadership begins somewhere far more intimate: in listening. “Progress happens only when expertise is matched by…
Bente Mikkelsen: “Success is Something We Build Together”
From the bedside to global reform, and why equity must be engineered, not hoped for “I think I chose medicine because it gave all the opportunities to address people, both at a national level, but also internationally. And it’s a…